Published in Cancer Res on August 01, 2004
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15
Pten regulates neuronal arborization and social interaction in mice. Neuron (2006) 6.11
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
Class I PI3K in oncogenic cellular transformation. Oncogene (2008) 3.90
The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A (2005) 3.72
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet (2012) 3.41
Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A (2007) 3.15
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer (2006) 3.04
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer (2008) 2.47
PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 1.90
Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions. Cancer Cell (2013) 1.74
Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme. Cancer Res (2008) 1.65
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res (2006) 1.63
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle (2009) 1.54
Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci U S A (2007) 1.54
Defining the blueprint of the cancer genome. Carcinogenesis (2008) 1.49
Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer (2008) 1.42
Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α. FEBS J (2015) 1.38
Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle (2008) 1.35
The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics (2007) 1.33
Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol (2012) 1.33
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol (2010) 1.27
Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol (2010) 1.27
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol (2008) 1.22
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle (2010) 1.22
Glioblastoma Multiforme Oncogenomics and Signaling Pathways. Clin Med Oncol (2009) 1.21
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch (2011) 1.19
High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations. PLoS One (2012) 1.09
Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. J Gastrointest Surg (2009) 1.04
Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res (2014) 1.02
Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol (2015) 1.01
PI3Kinase signaling in glioblastoma. J Neurooncol (2010) 1.01
Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma. PLoS One (2013) 1.00
Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. Biochem J (2007) 0.97
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res (2010) 0.97
The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. Front Oncol (2014) 0.96
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbecks Arch Surg (2008) 0.94
Mutations in PIK3CA are infrequent in neuroblastoma. BMC Cancer (2006) 0.93
Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma. J Gastrointest Oncol (2013) 0.93
RNAi knockdown of PIK3CA preferentially inhibits invasion of mutant PIK3CA cells. World J Gastroenterol (2011) 0.90
Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS One (2012) 0.88
Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 0.87
Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. PLoS One (2010) 0.87
The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets (2008) 0.86
Phosphatidylinositol 3-Kinase dependent upregulation of the epidermal growth factor receptor upon Flotillin-1 depletion in breast cancer cells. BMC Cancer (2013) 0.86
Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma. PLoS One (2014) 0.85
Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood Cancer (2012) 0.85
Occipital anaplastic oligodendroglioma with multiple organ metastases after a short clinical course: a case report and literature review. Diagn Pathol (2014) 0.85
MicroRNA-542-3p Suppresses Tumor Cell Invasion via Targeting AKT Pathway in Human Astrocytoma. J Biol Chem (2015) 0.85
Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects. Biophys Rev (2014) 0.84
Mutational profiling of kinases in glioblastoma. BMC Cancer (2014) 0.84
The mTOR signaling pathway as a treatment target for intracranial neoplasms. Neuro Oncol (2014) 0.84
Molecular neuropathology of gliomas. Int J Mol Sci (2009) 0.83
Carcinogenesis of PIK3CA. Hered Cancer Clin Pract (2013) 0.83
Matching mice to malignancy: molecular subgroups and models of medulloblastoma. Childs Nerv Syst (2012) 0.83
Mutations of the PIK3CA gene are rare in human glioblastoma. Acta Neuropathol (2005) 0.82
Targeting the PI3K pathway for cancer therapy. Future Med Chem (2012) 0.82
Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12) V-Ha-Ras transgenic mouse glioma model. Cancer Cell Int (2014) 0.81
The genetic signatures of pediatric high-grade glioma: no longer a one-act play. Semin Radiat Oncol (2014) 0.80
Absence of common somatic alterations in genes on 1p and 19q in oligodendrogliomas. PLoS One (2011) 0.80
Drosophila melanogaster as a model system for human brain cancers. Glia (2011) 0.80
PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. PLoS One (2016) 0.79
Structural basis of nSH2 regulation and lipid binding in PI3Kα. Oncotarget (2014) 0.79
PIK3CA mutations in mucinous cystic neoplasms of the pancreas. Pancreas (2014) 0.79
Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy. Toxicol Pathol (2013) 0.78
Targeted therapy in the treatment of malignant gliomas. Onco Targets Ther (2009) 0.78
The Phosphoinositide 3-Kinase p110α Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma. PLoS One (2015) 0.78
Diagnostic application of PIK3CA mutation analysis in Chinese esophageal cancer patients. Diagn Pathol (2014) 0.77
PIK3CA mutations in meningioma. Neuro Oncol (2016) 0.75
Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition. Oncotarget (2016) 0.75
VPS34 regulates TSC1/TSC2 heterodimer to mediate RheB and mTORC1/S6K1 activation and cellular transformation. Oncotarget (2016) 0.75
Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma. Sci Rep (2017) 0.75
The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors. Oncotarget (2016) 0.75
Common genetic variations in cell cycle and DNA repair pathways associated with pediatric brain tumor susceptibility. Oncotarget (2016) 0.75
PIK3CA polymorphisms associated with susceptibility to hepatocellular carcinoma. Int J Clin Exp Pathol (2015) 0.75
PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma. World J Gastroenterol (2017) 0.75
Mutations of the human interferon alpha-2b gene in brain tumor patients exposed to different environmental conditions. Cancer Gene Ther (2015) 0.75
Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR. Mol Diagn Ther (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Cancer genome landscapes. Science (2013) 25.33
International network of cancer genome projects. Nature (2010) 20.35
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Allelic variation in human gene expression. Science (2002) 11.42
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 9.04
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol (2007) 6.43
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
The antisense transcriptomes of human cells. Science (2008) 6.29
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Inactivation of hCDC4 can cause chromosomal instability. Nature (2004) 5.71
Mutational analysis of the tyrosine kinome in colorectal cancers. Science (2003) 5.43
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31
Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res (2009) 4.92
Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67
The predictive capacity of personal genome sequencing. Sci Transl Med (2012) 4.64
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature (2010) 4.53
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature (2012) 4.37
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med (2012) 4.11
A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Res (2007) 4.09
Digital karyotyping. Proc Natl Acad Sci U S A (2002) 3.96
Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med (2012) 3.92
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol (2009) 3.90
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell (2010) 3.82
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A (2011) 3.66
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Genetic progression and the waiting time to cancer. PLoS Comput Biol (2007) 3.57
Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther (2006) 3.56
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 3.55
Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc Natl Acad Sci U S A (2008) 3.52
Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science (2011) 3.49
Oncogenic mutations of PIK3CA in human cancers. Cell Cycle (2004) 3.47
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell (2013) 3.32
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov (2011) 3.27
Prevalence of somatic alterations in the colorectal cancer cell genome. Proc Natl Acad Sci U S A (2002) 3.25
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell (2009) 3.11
Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res (2007) 3.05
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst (2010) 3.00